Rong Zhou Sells 6,893 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 6,893 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the completion of the transaction, the executive vice president now owns 118,388 shares of the company’s stock, valued at $5,786,805.44. This represents a 5.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Monday, August 26th, Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $48.35, for a total value of $193,400.00.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $45.06 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The firm has a market capitalization of $2.17 billion, a P/E ratio of 15.02, a P/E/G ratio of 0.92 and a beta of 0.82. The business’s 50-day simple moving average is $48.42 and its 200-day simple moving average is $44.34.

Analyst Ratings Changes

A number of analysts recently commented on AMPH shares. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $63.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AMPH. Aurora Investment Counsel increased its position in shares of Amphastar Pharmaceuticals by 0.4% in the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after acquiring an additional 232 shares in the last quarter. GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Crossmark Global Holdings Inc. increased its holdings in Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock valued at $452,000 after purchasing an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after purchasing an additional 301 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.